MedPath

Xention Ltd.

🇬🇧United Kingdom
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.xention.com
Clinical Trials
Related News

Bioequivalence Study of Capsule and Tablet Formulations of TA-8995

Phase 1
Completed
Conditions
Dyslipidaemia
Interventions
First Posted Date
2015-08-14
Last Posted Date
2016-01-29
Lead Sponsor
Xention Ltd
Target Recruit Count
26
Registration Number
NCT02523391
Locations
🇬🇧

Covance Clinical Research Unit Ltd, Leeds, United Kingdom

ADME Study in Healthy Male Subjects With TA-8995

Phase 1
Completed
Conditions
Dyslipidemia
Interventions
First Posted Date
2015-04-03
Last Posted Date
2016-10-03
Lead Sponsor
Xention Ltd
Target Recruit Count
6
Registration Number
NCT02408055
Locations
🇬🇧

Covance Clinical Research Unit Ltd, Leeds, United Kingdom

Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103

Phase 1
Completed
Conditions
Atrial Fibrillation
Interventions
Drug: Placebo
Drug: 10mg XEN-D0103
Drug: 200mg XEN-D0103
Drug: 30mg XEN-D0103
Drug: 60mg XEN-D0103
Drug: 120mg XEN-D0103
Drug: 150mg XEN-D0103
First Posted Date
2015-03-17
Last Posted Date
2015-03-18
Lead Sponsor
Xention Ltd
Target Recruit Count
87
Registration Number
NCT02390258
Locations
🇬🇧

ICON Development Solutions, Manchester, United Kingdom

A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)

Phase 1
Completed
Conditions
Elevated Lp(a)
Interventions
Drug: Placebo
First Posted Date
2014-09-16
Last Posted Date
2015-02-16
Lead Sponsor
Xention Ltd
Target Recruit Count
42
Registration Number
NCT02241772
Locations
🇩🇰

Herlev Hospital, Herlev, Denmark

Study of the Electrocardiographic Effects of TA-8995

Phase 1
Completed
Conditions
Dyslipidaemia
Interventions
Drug: Placebo
First Posted Date
2014-09-16
Last Posted Date
2015-02-16
Lead Sponsor
Xention Ltd
Target Recruit Count
136
Registration Number
NCT02241759
Locations
🇬🇧

Covance Clinical Research Unit Ltd, Leeds, United Kingdom

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD

Phase 2
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Drug: Placebo
First Posted Date
2014-09-08
Last Posted Date
2015-07-15
Lead Sponsor
Xention Ltd
Target Recruit Count
27
Registration Number
NCT02233686
Locations
🇬🇧

Medicines Evaluation Unit, Manchester, United Kingdom

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough

Phase 2
Completed
Conditions
Chronic Idiopathic Cough
Interventions
Drug: Placebo
First Posted Date
2014-09-08
Last Posted Date
2015-07-15
Lead Sponsor
Xention Ltd
Target Recruit Count
18
Registration Number
NCT02233699
Locations
🇮🇪

Belfast City Hospital, Belfast, Ireland

🇬🇧

University Hospital of South Manchester, Manchester, United Kingdom

A Preliminary Drug Drug Interaction Study With TA-8995

Phase 1
Completed
Conditions
Pharmacokinetic Interactions
Interventions
First Posted Date
2014-04-28
Last Posted Date
2016-10-03
Lead Sponsor
Xention Ltd
Target Recruit Count
18
Registration Number
NCT02124954
Locations
🇬🇧

Covance, Leeds, United Kingdom

TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)

Phase 2
Completed
Conditions
Dyslipidemia
Interventions
Drug: TA-8995 0mg (placebo)
Drug: Placebo Statin
First Posted Date
2013-10-28
Last Posted Date
2014-08-21
Lead Sponsor
Xention Ltd
Target Recruit Count
364
Registration Number
NCT01970215
Locations
🇩🇰

H:S Amager Hospital, Copenhagen, Denmark

🇩🇰

Sydvestjysk Sygehus, Esbjerg, Denmark

🇩🇰

Herlev University Hospital, Herlev, Denmark

and more 14 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy